These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 16370927)
1. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Perry HD; Donnenfeld ED Expert Opin Pharmacother; 2006 Jan; 7(1):99-107. PubMed ID: 16370927 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. Sandoval HP; De Castro LE; Vroman DT; Solomon KD J Ocul Pharmacol Ther; 2006 Aug; 22(4):251-7. PubMed ID: 16910866 [TBL] [Abstract][Full Text] [Related]
4. Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis. Schechter BA Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):507-11. PubMed ID: 18433352 [TBL] [Abstract][Full Text] [Related]
5. A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. Sandoval HP; Fernández de Castro LE; Vroman DT; Solomon KD Clin Ophthalmol; 2007 Dec; 1(4):367-71. PubMed ID: 19668513 [TBL] [Abstract][Full Text] [Related]
6. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. Holzer MP; Solomon KD; Sandoval HP; Vroman DT J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716 [TBL] [Abstract][Full Text] [Related]
7. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Heier J; Cheetham JK; Degryse R; Dirks MS; Caldwell DR; Silverstone DE; Rosenthal A Am J Ophthalmol; 1999 Mar; 127(3):253-9. PubMed ID: 10088733 [TBL] [Abstract][Full Text] [Related]
9. Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked study. Solomon KD; Vroman DT; Barker D; Gehlken J J Cataract Refract Surg; 2001 Aug; 27(8):1232-7. PubMed ID: 11524195 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Price MO; Price FW Curr Med Res Opin; 2004 Dec; 20(12):2015-9. PubMed ID: 15701218 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. Simone JN; Pendelton RA; Jenkins JE J Cataract Refract Surg; 1999 May; 25(5):699-704. PubMed ID: 10330648 [TBL] [Abstract][Full Text] [Related]
12. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. Duong HV; Westfield KC; Chalkley TH J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of preoperative versus postoperative ketorolac tromethamine 0.5% in reducing inflammation after cataract surgery. El-Harazi SM; Ruiz RS; Feldman RM; Villanueva G; Chuang AZ J Cataract Refract Surg; 2000 Nov; 26(11):1626-30. PubMed ID: 11084270 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Stewart R; Grosserode R; Cheetham JK; Rosenthal A Clin Ther; 1999 Apr; 21(4):723-32. PubMed ID: 10363737 [TBL] [Abstract][Full Text] [Related]
15. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Wittpenn JR; Silverstein S; Heier J; Kenyon KR; Hunkeler JD; Earl M; Am J Ophthalmol; 2008 Oct; 146(4):554-560. PubMed ID: 18599019 [TBL] [Abstract][Full Text] [Related]